Josep M Del Bas1, Antoni Caimari2, Maria Isabel Rodriguez-Naranjo1, Caroline E Childs3, Carolina Paras Chavez3, Annette L West3, Elizabeth A Miles3, Lluis Arola4, Philip C Calder5. 1. Nutrition and Health Research Group, Technological Center for Nutrition and Health, Tecnio, Campus of International Excellence Southern Catalonia (CEICS), Reus, Spain; 2. Nutrition and Health Research Group, Technological Center for Nutrition and Health, Tecnio, Campus of International Excellence Southern Catalonia (CEICS), Reus, Spain; antoni.caimari@ctns.cat. 3. Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; 4. Nutrition and Health Research Group, Technological Center for Nutrition and Health, Tecnio, Campus of International Excellence Southern Catalonia (CEICS), Reus, Spain; Nutrigenomics Research Group, Department of Biochemistry and Biotechology, University Rovira i Virgili, Tarragona, Spain; and. 5. Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; National Institute for Health Research Southampton Biomedical Research Centre, University Hospital Southampton National Health Service Foundation Trust and University of Southampton, Southampton, United Kingdom.
Abstract
BACKGROUND: Plasma lysophospholipids have emerged as signaling molecules with important effects on inflammation, insulin resistance, and fatty liver disease, each of which is linked closely to obesity. Dietary n-3 (ω-3) polyunsaturated fatty acids (PUFAs) may be able to improve these conditions. OBJECTIVE: The objective of this study was to assess the response of plasma lysophospholipids to obesity, n-3 PUFA consumption, and a high-fat meal challenge to better understand the role of lysophospholipid metabolism in the progression of obesity-related disorders. DESIGN: We determined the concentrations of 8 lysophosphatidylcholines, 11 lysophosphatidylethanolamines, and 7 lysophosphatidylinositols in the plasma of 34 normal-weight and 38 obese subjects randomly assigned toconsume corn oil (control) or n-3 PUFA-rich fish oil (3 g/d; n = 15-19/group) for 90 d. Blood samples were collected on the last day of the study under fasting conditions and 6 h after a high-fat meal (1135 kcal, 86 g fat) challenge. The profile of secreted lysophospholipids was studied in HepG2 cells under palmitate-induced steatosis. RESULTS: Obese and normal-weight subjects had different profiles of plasma lysophospholipids. A multivariate combination of the 26 lysophospholipids could discriminate between normal-weight and obese subjects with an accuracy of 98%. The high-fat meal challenge altered the concentration of plasma lysophosphatidylcholines in an oil treatment-dependent manner in normal-weight but not obese subjects, suggesting that obesity impairs the sensitivity of lysophospholipid metabolism to n-3 PUFAs. Noncytotoxic steatosis in HepG2 cells affected the secretion pattern of lysophospholipids, partially resembling the changes observed in the plasma of obese subjects. CONCLUSIONS:Obesity has a substantial impact on lysophospholipid metabolism, altering the plasma lysophospholipid profile and abolishing its sensitivity to dietary n-3 PUFAs. These effects could contribute to the onset or progression of alterations associated with obesity, such as inflammation, insulin resistance, and fatty liver disease. This trial was registered at www.controlled-trials.com as ISRCTN96712688.
RCT Entities:
BACKGROUND: Plasma lysophospholipids have emerged as signaling molecules with important effects on inflammation, insulin resistance, and fatty liver disease, each of which is linked closely to obesity. Dietary n-3 (ω-3) polyunsaturated fatty acids (PUFAs) may be able to improve these conditions. OBJECTIVE: The objective of this study was to assess the response of plasma lysophospholipids to obesity, n-3 PUFA consumption, and a high-fat meal challenge to better understand the role of lysophospholipid metabolism in the progression of obesity-related disorders. DESIGN: We determined the concentrations of 8 lysophosphatidylcholines, 11 lysophosphatidylethanolamines, and 7 lysophosphatidylinositols in the plasma of 34 normal-weight and 38 obese subjects randomly assigned to consume cornoil (control) or n-3 PUFA-rich fish oil (3 g/d; n = 15-19/group) for 90 d. Blood samples were collected on the last day of the study under fasting conditions and 6 h after a high-fat meal (1135 kcal, 86 g fat) challenge. The profile of secreted lysophospholipids was studied in HepG2 cells under palmitate-induced steatosis. RESULTS:Obese and normal-weight subjects had different profiles of plasma lysophospholipids. A multivariate combination of the 26 lysophospholipids could discriminate between normal-weight and obese subjects with an accuracy of 98%. The high-fat meal challenge altered the concentration of plasma lysophosphatidylcholines in an oil treatment-dependent manner in normal-weight but not obese subjects, suggesting that obesity impairs the sensitivity of lysophospholipid metabolism to n-3 PUFAs. Noncytotoxic steatosis in HepG2 cells affected the secretion pattern of lysophospholipids, partially resembling the changes observed in the plasma of obese subjects. CONCLUSIONS:Obesity has a substantial impact on lysophospholipid metabolism, altering the plasma lysophospholipid profile and abolishing its sensitivity to dietary n-3 PUFAs. These effects could contribute to the onset or progression of alterations associated with obesity, such as inflammation, insulin resistance, and fatty liver disease. This trial was registered at www.controlled-trials.com as ISRCTN96712688.
Authors: Zora Djuric; D Kim Turgeon; Ananda Sen; Jianwei Ren; Kirk Herman; Devon Ramaswamy; Lili Zhao; Mack T Ruffin; Daniel P Normolle; William L Smith; Dean E Brenner Journal: Cancer Prev Res (Phila) Date: 2017-11-13
Authors: Fred K Tabung; Liming Liang; Tianyi Huang; Raji Balasubramanian; Yibai Zhao; Paulette D Chandler; JoAnn E Manson; Elizabeth M Cespedes Feliciano; Kathleen M Hayden; Linda Van Horn; Clary B Clish; Edward L Giovannucci; Kathryn M Rexrode Journal: Clin Nutr Date: 2019-06-17 Impact factor: 7.324
Authors: Venkatesh L Murthy; Matthew Nayor; Mercedes Carnethon; Jared P Reis; Donald Lloyd-Jones; Norrina B Allen; Robert Kitchen; Paolo Piaggi; Lyn M Steffen; Ramachandran S Vasan; Jane E Freedman; Clary B Clish; Ravi V Shah Journal: Diabetologia Date: 2022-01-18 Impact factor: 10.122
Authors: Yifan Shen; Ananda Sen; D Kim Turgeon; Jianwei Ren; Gillian Graifman; Mack T Ruffin; William L Smith; Dean E Brenner; Zora Djuric Journal: Nutr Cancer Date: 2021-03-24 Impact factor: 2.816
Authors: Susana Suárez-García; Josep M Del Bas; Antoni Caimari; Rosa M Escorihuela; Lluís Arola; Manuel Suárez Journal: PLoS One Date: 2017-02-13 Impact factor: 3.240